IDEAYA Biosciences Inc at Citi Global Technology Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yigal Nochomovitz - Citigroup - Analyst : So, you all have nonoverlapping sets of targets that you're pursuing as you just nicely articulated. But nonetheless, there's certainly themes in terms of developing targeted therapies for oncology and then other indications. So, if you could talk a bit about some of the challenges and opportunities. What are the design considerations? How do you think about target selection when designing a targeted therapy? How do you think about a biomarker strategy as well as potential combinations? At a high level, what's the thought process, given of course, you're playing in different sandboxes?

Question: Yigal Nochomovitz - Citigroup - Analyst : It sounds like you're referencing, I assume, Project Optimus, to some extent. You're arguing for it as a way to help us advance the dose selection. Other thoughts, as far as Project Optimus, do you see it as a positive or a hindrance? How much is it slowing down or improving the dose selection?

Question: Yigal Nochomovitz - Citigroup - Analyst : What about the other design consideration? This is relatively specific question but the covalent versus non-covalent inhibitors, do you -- how did you try to bucket into one of those or you just look for the best drug and try to steer away from one class of the other class?

Question: Yigal Nochomovitz - Citigroup - Analyst : I know you mentioned, some of you do in-licensing, but you also do in-house discovery. So there's AI now, there's machine learning. There's a whole -- there's a lot of advanced algorithms to help design protein-protein interactions to design molecules. Are you leveraging that in your work and your discovery work to find better inhibitors or to understand binding interactions better? How much does that play a role in the early discovery for you guys?

Question: Yigal Nochomovitz - Citigroup - Analyst : I know, yeah.

Question: Yigal Nochomovitz - Citigroup - Analyst : Yeah. Okay.

Question: Yigal Nochomovitz - Citigroup - Analyst : Paul, if I could ask you a little movement. Let's move into some more pipeline specific questions so we can give each of you a chance to talk about where things stand in development. So you have the Phase 2 data for daro and crizotinib in the frontline (inaudible), but you're going to have some new data soon, I believe, at ESMO, the ctDNA data. Can you just talk a bit about what we should expect to see there and how that will further inform our understanding of the response rates are relative to what we've seen already.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. Michael, you mentioned it already, we're very close to the data -- the pivotal data for revumenib, KMT2A, AML and ALL. Tell us about the process there. Are you close to getting the trial data cleaned and data locked? What can you share in terms of what would be considered a successful outcome of that study? And then if you could talk about the NPM1 enrollment and where that stands to.

Question: Yigal Nochomovitz - Citigroup - Analyst : And just to explain to everyone for those less familiar. To put them back on drug after the transplant, will that accrue to the duration in the way you do the math?

Question: Yigal Nochomovitz - Citigroup - Analyst : Matt, you mentioned the EGFR/HER22 Exon 20, 114. The data is coming up at ESMO, if I'm not mistaken. Just remind us what the pitch is there in terms of the differentiation and the better brain penetration? And what would a good readout look like for you for this initial Phase 1?

Question: Yigal Nochomovitz - Citigroup - Analyst : And will you have enough information to get to an RP2D by that point? Or that will take additional exploration?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay.

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. Back to you, Paul. Maybe, if you could talk a little bit about the MAT2A inhibitor for solid tumors, the 397. Obviously, there's been a lot of movement in that space recently with Mirati and Amgen. Could you talk about the overall strategy for 397 and the combo approach with the Amgen PRMT5? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 06, 2023 / 5:00PM, IDYA.OQ - IDEAYA Biosciences Inc at Citi Global Technology Conference

Question: Yigal Nochomovitz - Citigroup - Analyst : You said when that data are coming?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay. And then Michael, beyond AML, talk about some of the solid tumor approaches with revumenib. You've got a study in frontline CRC --

Question: Yigal Nochomovitz - Citigroup - Analyst : Frontline. There is a CRC study. Can you just talk a little bit more about that and the strategy there for the solid tumors?

Question: Yigal Nochomovitz - Citigroup - Analyst : And then obviously, there's a few other players in the menin inhibitor space. So just give me a chance to sort of comment in terms of how you see revumenib in this competitive positioning relative to the field?

Question: Yigal Nochomovitz - Citigroup - Analyst : And then, last question. Back to you, Matt. Let's talk about the CD73 in the multiple myeloma angle. As far as I know, you're the only CD73 that's in myeloma. Talk about the scientific clinical rationale for that and how that came about and what you want to see in the first dataset coming up this year?

Question: Yigal Nochomovitz - Citigroup - Analyst : And these would be patients that have failed (inaudible) the proteasome inhibitors and so forth?